Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Aerie Pharmaceuticals stock

Learn how to easily invest in Aerie Pharmaceuticals stock.

Aerie Pharmaceuticals is a drug manufacturers-specialty & generic business based in the US. Aerie Pharmaceuticals shares (AERI) are listed on the NASDAQ and all prices are listed in US Dollars. Aerie Pharmaceuticals employs 376 staff and has a trailing 12-month revenue of around $213.9 million.

How to buy Aerie Pharmaceuticals stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – AERI. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award


  • Easy to use platform with $0 stock trading & no annual fees
  • Social trading allows you to copy popular portfolios
  • FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100

Promoted for options trading


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+

Aerie Pharmaceuticals stock price (NASDAQ: AERI)

Use our graph to track the performance of AERI stocks over time.

Aerie Pharmaceuticals shares at a glance

Information last updated 2023-02-26.
Latest market close$0.00
52-week range$4.81 - $15.37
50-day moving average $15.19
200-day moving average $10.24
Wall St. target price$15.35
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.47

Buy Aerie Pharmaceuticals stocks from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 6 of 6
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
Stocks, Options, ETFs, Cryptocurrency
FINDER EXCLUSIVE: Get a guaranteed $15 bonus
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency, Futures
Get $100 - $2,000
when you you open and fund an account with $5,000 to $100,000+
Highly commended for Best Derivatives Trading Platform award.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs, Treasury Bills
Get $50 - $700
when you open and fund an account with $10,000 - $250,000+
Stocks, Bonds, Options, Mutual funds, ETFs, Futures
Get up to $600 or more
when you open and fund a new account.
E*TRADE offers commission-free stocks, access to mutual funds and advanced trading tools. Other fees apply.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Is it a good time to buy Aerie Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aerie Pharmaceuticals price performance over time

Historical closes compared with the close of $0 from 2022-12-02

1 week (2023-03-17) nan%
1 month (2023-02-24) nan%
3 months (2022-12-24) nan%
6 months (2022-09-28) -100.00%
1 year (2022-03-25) -100.00%
2 years (2021-03-26) -100.00%
3 years (2020-03-27) 13.05
5 years (2018-03-28) 53.75

Aerie Pharmaceuticals financials

Revenue TTM $213.9 million
Gross profit TTM $167.3 million
Return on assets TTM -4.59%
Return on equity TTM -2255.01%
Profit margin -17.09%
Book value $-3.32
Market capitalisation $753.6 million

TTM: trailing 12 months

Aerie Pharmaceuticals share dividends

We're not expecting Aerie Pharmaceuticals to pay a dividend over the next 12 months.

Aerie Pharmaceuticals share price volatility

Over the last 12 months, Aerie Pharmaceuticals's shares have ranged in value from as little as $4.81 up to $15.37. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aerie Pharmaceuticals's is -0.062. This would suggest that Aerie Pharmaceuticals's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Aerie Pharmaceuticals has bucked the trend.

Aerie Pharmaceuticals overview

Aerie Pharmaceuticals, Inc. , a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

Frequently asked questions

What percentage of Aerie Pharmaceuticals is owned by insiders or institutions?
Currently 1.791% of Aerie Pharmaceuticals shares are held by insiders and 102.995% by institutions.
How many people work for Aerie Pharmaceuticals?
Latest data suggests 376 work at Aerie Pharmaceuticals.
When does the fiscal year end for Aerie Pharmaceuticals?
Aerie Pharmaceuticals's fiscal year ends in December.
Where is Aerie Pharmaceuticals based?
Aerie Pharmaceuticals's address is: 4301 Emperor Boulevard, Durham, NC, United States, 27703
What is Aerie Pharmaceuticals's ISIN number?
Aerie Pharmaceuticals's international securities identification number is: US00771V1089
What is Aerie Pharmaceuticals's CUSIP number?
Aerie Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 00771V108

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site